It is increasingly evident that cancer results from altered organ homeostasis rather than from deregulated control of single cells or groups of cells. This applies especially to epithelial cancer, the most common form of human solid tumors and a major cause of cancer lethality. In the vast majority of cases, in situ epithelial cancer lesions do not progress into malignancy, even if they harbor many of the genetic changes found in invasive and metastatic tumors. While changes in tumor stroma are frequently viewed as secondary to changes in the epithelium, recent evidence indicates that they can play a primary role in both cancer progression and initiation. These processes may explain the phenomenon of field cancerization, i.e., the occurrence of multifocal and recurrent epithelial tumors that are preceded by and associated with widespread changes of surrounding tissue or organ “fields.”
G. Paolo Dotto
Title and authors | Publication | Year |
---|---|---|
ΔNp63 in squamous cell carcinoma: defining the oncogenic routes affecting epigenetic landscape and tumour microenvironment
V Gatti, C Fierro, M AnnicchiaricoPetruzzelli, G Melino, A Peschiaroli |
Molecular Oncology | 2019 |
Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics
SR y Cajal, S Hümmer, V Peg, XM Guiu, ID Torres, J Castellvi, E MartinezSaez, J HernandezLosa |
Histopathology | 2019 |
Biochemical Changes in Irradiated Oral Mucosa: A FTIR Spectroscopic Study
H Ukkonen, S Vuokila, J Mikkonen, H Dekker, E Schulten, E Bloemena, A Koistinen, T Valdez, A Kullaa, S Singh |
Biosensors | 2019 |
Leveraging Spatial Variation in Tumor Purity for Improved Somatic Variant Calling of Archival Tumor Only Samples
RF Halperin, WS Liang, S Kulkarni, EE Tassone, J Adkins, D Enriquez, NL Tran, NC Hank, J Newell, C Kodira, R Korn, ME Berens, S Kim, SA Byron |
Frontiers in Oncology | 2019 |
Reactive oxygen species: a volatile driver of field cancerization and metastasis
Z Liao, D Chua, NS Tan |
Molecular Cancer | 2019 |
Epigenetic Field Cancerization in Gastric Cancer: microRNAs as Promising Biomarkers
AL Pereira, L Magalhães, FC Moreira, L Reis-das-Mercês, AF Vidal, AM Ribeiro-dos-Santos, S Demachki, AK Anaissi, RM Burbano, P Albuquerque, SE dos Santos, PP de Assumpção, ÂK Ribeiro-dos-Santos |
Journal of Cancer | 2019 |
CSL controls telomere maintenance and genome stability in human dermal fibroblasts
G Bottoni, A Katarkar, B Tassone, S Ghosh, A Clocchiatti, S Goruppi, P Bordignon, P Jafari, F Tordini, T Lunardi, W Hoetzenecker, V Neel, J Lingner, GP Dotto |
Nature Communications | 2019 |
Role of Nicotinamide in Genomic Stability and Skin Cancer Chemoprevention
L Fania, C Mazzanti, E Campione, E Candi, D Abeni, E Dellambra |
International journal of molecular sciences | 2019 |
Precision medicine for human cancers with Notch signaling dysregulation (Review)
M Katoh, M Katoh |
International journal of molecular medicine | 2019 |
GIDB: a knowledge database for the automated curation and multidimensional analysis of molecular signatures in gastrointestinal cancer
Y Wang, Y Wang, S Wang, Y Tong, L Jin, H Zong, R Zheng, J Yang, Z Zhang, E Ouyang, M Zhou, X Zhang |
Database | 2019 |
High immune cytolytic activity in tumor‐free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue
X Gu, L Boldrup, PJ Coates, R Fahraeus, L Wang, T Wilms, L NorbergSpaak, N Sgaramella, K Nylander |
The Journal of Pathology: Clinical Research | 2019 |
The role of clonal communication and heterogeneity in breast cancer
A Martín-Pardillos, ÁV Chiva, GB Vargas, PH Blanco, RP Cid, PJ Guijarro, S Hümmer, EB Serrano, A Rodriguez-Casanova, Á Diaz-Lagares, J Castellvi, S Miravet-Verde, L Serrano, M Lluch-Senar, V Sebastian, A Bribian, L López-Mascaraque, R López-López, SR y Cajal |
BMC Cancer | 2019 |
Fibroblast growth factor 7 signalling is disrupted in colorectal cancer and is a potential marker of field cancerisation
A Patel, G Tripathi, P McTernan, K Gopalakrishnan, O Ali, E Spector, N Williams, RP Arasaradnam |
Journal of Gastrointestinal Oncology | 2019 |